Evidence map›Paper›PMID 26658258›Full record

ArticlePloS one2015

Clobetasol and Halcinonide Act as Smoothened Agonists to Promote Myelin Gene Expression and RxRγ Receptor Activation.

Giampiero Porcu, Eliseo Serone, Velia De Nardis, Daniele Di Giandomenico, Giuseppe Lucisano, Marco Scardapane, Anna Poma, Antonella Ragnini-Wilson

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 44 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. The Current Challenges for Drug Discovery in CNS Remyelination.International journal of molecular sciences · 2021
    Review
  16. Article
  17. Article
  18. Structural and Functional Aspects of the Neurodevelopmental GeneFrontiers in molecular neuroscience · 2021
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Giampiero PorcuDepartment of Biology, University of Rome "Tor Vergata", Rome, Italy.
Eliseo SeroneDepartment of Translational Pharmacology, Fondazione Mario Negri Sud, S. Maria Imbaro (CH), Italy.
Velia De NardisDepartment of Translational Pharmacology, Fondazione Mario Negri Sud, S. Maria Imbaro (CH), Italy.
Daniele Di GiandomenicoDepartment of Translational Pharmacology, Fondazione Mario Negri Sud, S. Maria Imbaro (CH), Italy.
Giuseppe LucisanoDepartment of Translational Pharmacology, Fondazione Mario Negri Sud, S. Maria Imbaro (CH), Italy.
Marco ScardapaneDepartment of Translational Pharmacology, Fondazione Mario Negri Sud, S. Maria Imbaro (CH), Italy.
Anna PomaDepartment of Life, Health and Environmental Sciences, University of L'Aquila, L'Aquila, Italy.
Antonella Ragnini-WilsonDepartment of Biology, University of Rome "Tor Vergata", Rome, Italy.
Mario Negri Sud Foundation · ITCenter for Outcomes Research and Clinical Epidemiology · ITUniversity of L'Aquila · ITUniversity of Rome Tor Vergata · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of the causes of permanent disability in chronic multiple sclerosis patients is the inability of oligodendrocyte progenitor cells (OPCs) to terminate their maturation program at lesions. To identify key regulators of myelin gene expression acting at the last stages of OPC maturation we developed a drug repositioning strategy based on the mouse immortalized oligodendrocyte (OL) cell line Oli-neu brought to the premyelination stage by stably expressing a key factor regulating the last stages of OL maturation. The Prestwick Chemical Library of 1,200 FDA-approved compound(s) was repositioned at three dosages based on the induction of Myelin Basic Protein (MBP) expression. Drug hits were further validated using dosage-dependent reproducibility tests and biochemical assays. The glucocorticoid class of compounds was the most highly represented and we found that they can be divided in three groups according to their efficacy on MBP up-regulation. Since target identification is crucial before bringing compounds to the clinic, we searched for common targets of the primary screen hits based on their known chemical-target interactomes, and the pathways predicted by top ranking compounds were validated using specific inhibitors. Two of the top ranking compounds, Halcinonide and Clobetasol, act as Smoothened (Smo) agonists to up-regulate myelin gene expression in the Oli-neuM cell line. Further, RxRγ activation is required for MBP expression upon Halcinonide and Clobetasol treatment. These data indicate Clobetasol and Halcinonide as potential promyelinating drugs and also provide a mechanistic understanding of their mode of action in the pathway leading to myelination in OPCs. Furthermore, our classification of glucocorticoids with respect to MBP expression provides important novel insights into their effects in the CNS and a rational criteria for their choice in combinatorial therapies in de-myelinating diseases.

Indexed as

AnimalsAnti-Inflammatory AgentsCell LineClobetasolCytoskeletal ProteinsDrug RepositioningGene ExpressionHalcinonideImmunoblottingMiceMicroscopy, FluorescenceMuscle ProteinsMyelin Basic ProteinMyelin SheathOligodendrogliaRetinoid X Receptor gammaAnti-Inflammatory AgentsClobetasolCytoskeletal ProteinsHalcinonideMuscle ProteinsMyelin Basic Proteinmyelin gene regulatory factor, mouseRetinoid X Receptor gammaSmtn protein, mouseTranscription Factors

Identifiers

PMID26658258
PMCPMC4689554
OpenAlexW2189933365

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.